Indoco Remedies Limited

Disclosure under SEBI Takeover Regulations

KFPT along with Aruna Suresh Kare acquired shares of Indoco Remedies via direct and indirect transfers for succession planning, increasing their stake.

Disclosure under SEBI Takeover Regulations

Kare Family Private Trust (KFPT) and Aruna Suresh Kare acquired shares of Indoco Remedies via direct and indirect transfers for succession planning, increasing their stake.

Retirement of Senior Management Personnel at Indoco Remedies

Mr. Ajay Karajagi (President - Sales & Marketing), a Senior Management Personnel of Indoco Remedies Limited, will retire from the Company effective from the close of business hours on 30th November, 2025.

Promoter Group proposes acquisition of shares in Indoco Remedies

Promoter group intends to acquire shares via inter-se transfer for succession planning. KFPT and Aruna Suresh Kare to acquire direct and indirect stakes in Indoco Remedies, with acquisition planned on or after 25 Nov 2025.

Indoco Remedies Reports Q2 FY26 Earnings Uptick; USFDA & European Business Updates

Indoco Remedies released its Q2 FY26 earnings call transcript, reporting revenue growth, 0 USFDA observations for its API plant, and ANDA approval for Rivaroxaban. Management expects improved performance and double-digit growth in Europe.

Indoco Remedies Announces Unaudited Standalone and Consolidated Financial Results Publication

Indoco Remedies announced publication of unaudited financial results for quarter and half year ended September 30, 2025, in Business Standard and Mumbai Lakshadeep on November 7, 2025. Results approved by Board on November 6, 2025.

Indoco Remedies Limited Announces Audio Recording of Earnings Conference Call

Indoco Remedies Limited has released the audio recording of its earnings conference call for the quarter and half year ended September 30, 2025. The call took place on November 6, 2025.

Indoco Remedies Reports Q2 FY26 Results: Revenue Up, Consolidated Net Loss, Subsidiary Going Concern Noted

Indoco Remedies reported Q2 FY26 standalone revenue up 8.8% and profit up. Consolidated revenue increased, but a net loss was posted. Auditors noted going concern uncertainty for two subsidiaries.

Indoco Remedies provides ₹25 Crore corporate guarantee for wholly-owned subsidiary

Indoco Remedies' Directors approved a ₹25 Crore corporate guarantee for its wholly-owned subsidiary, Warren Remedies, for HDFC Bank loans, creating a contingent liability for Indoco.

Indoco Remedies participates in 'Saksham Niveshak' campaign for unclaimed dividends and KYC updates

Indoco Remedies is participating in the 'Saksham Niveshak' campaign from July 28 to November 6, 2025, to help shareholders claim unpaid dividends and update KYC details to avoid transfer to IEPF.

Indoco Remedies Announces Earnings Conference Call for Q2FY26

Indoco Remedies announces an earnings conference call on 6th November, 2025, at 3:30 P.M. IST to discuss Q2FY26 financial results. Management will be represented by Ms. Aditi Panandikar, Mr. Sundeep V Bambolkar and Mr. Pramod Ghorpade.

Indoco Remedies clarifies on spurt in trading volume, states no undisclosed material information

Indoco Remedies clarified to NSE that the recent spurt in trading volume is market-driven, with no undisclosed material information or impending announcements affecting its scrip.

Indoco Remedies Submits Compliance Certificate under SEBI (Depositories and Participants) Regulations, 2018

Indoco Remedies submitted its compliance certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September 2025, confirming dematerialization process compliance.

ICRA reaffirms and assigns credit ratings for Indoco Remedies

Indoco Remedies to Host Virtual Analyst/Institutional Investor Meet on September 25, 2025

USFDA Completes Inspection of Indoco's API Facility with Zero Observations

Indoco Remedies Holds 78th AGM, Declares ₹0.20 Final Dividend for FY25

Indoco Remedies enters into sale and lease back agreements

Indoco Remedies announces 78th AGM on September 11, 2025 via VC/OAVM

Indoco Remedies enters into sale and lease back agreement for Waluj facility.

Indoco Remedies Q1 Revenue at ₹3,838 Lakhs, Up 12.5% Q-o-Q

Indoco Remedies Receives EU GMP Compliance for Goa Sterile Drug Product Facility